AlphAIAlphAI — Financial news for AI agents
simplywall.st$AUPH

Aurinia Stock Jumps After Earnings Beat And Pipeline Progress

Aurinia Pharmaceuticals reported Q2 revenue of $83.2M and net income of $37.4M, with LUPKYNIS sales at $79.4M. The company initiated new clinical studies for aritinercept. Analysts forecast revenue of $453.5M and earnings of $169.9M by 2029, with a 7% upside potential. The stock rose on earnings beat and pipeline progress.

Original reporting
simplywall.st
Published Sep 17, 2026, 9:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 9:43 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Aurinia Stock Jumps After Earnings Beat And Pipeline Progress — source image
Source · simplywall.st
Decision brief

The 30-second read

$AUPHBullishMed
01

Why it matters

Earnings beat and pipeline updates provide fresh data for valuation models.

02

Market read

The earnings release introduces new financial metrics and pipeline milestones that can move the stock.

03

What to watch

Phase 4 combination study outcomes remain uncertain and could affect future guidance.

Relevance 7/10Novelty 7/10Timing: post‑market release

Background

Aurinia is a Nasdaq‑listed biotech focused on lupus nephritis treatment.

Company-level read

Ticker impact

$AUPHBullishMedium confidence
Context

Aurinia Pharmaceuticals reported Q2 revenue of $83.2M, net income $37.4M and LUPKYNIS sales of $79.4M, marking an earnings beat and pipeline progress.

Expected impact

Potential short‑term price rally on earnings beat.

Evidence & confidence

Strong revenue and profit beat, plus pipeline news, provide a fresh catalyst for traders.

Market effects

Sector

Positive signal for autoimmune biotech sector as LUPKYNIS demand rises.

Regional

U.S. biotech investors may re‑price similar small‑cap lupus therapies.

Global

Limited to niche biotech segment.

Counterpoint

What could challenge this read

Heavy reliance on a single product poses risk if patent or pricing pressures emerge.

Key entities

  • Company
    Aurinia Pharmaceuticals

    Biotech firm reporting earnings and pipeline progress.

Read at source← All news

Also covered by

1 outlet

Related articles

$AUPHMedAI 8/10

Aurinia Skids on Results

Aurinia Pharmaceuticals reported Q3 and YTD 2026 revenue of $83.7M and $244.6M, up 14% and 19% YoY. LUPKYNIS sales rose 12% and 18% YoY for the same periods. License, collaboration, and royalty revenue increased 54% and 39% YoY. Net income before taxes grew 21% and 67% YoY.

baystreet.ca
$AUPHHigh

Aurinia Pharmaceuticals stock falls 3% on Q3 miss, soft guidance

Aurinia Pharmaceuticals (AUPH) reported Q3 earnings of $0.23 per share, missing estimates by $0.01, and revenue of $83.7M, slightly below expectations. Shares fell 3.43% premarket. The company raised 2026 revenue guidance to $325M-$330M, below analyst consensus. LUPKYNIS sales grew 12% YoY to $79.4M. The company also initiated a Phase 4 study for lupus nephritis treatments.

investing.com
$AUPHHigh

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals Inc. (AUPH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress EDMONTON, Alberta – October 30, 2026 – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial resul

SEC EDGAR 8-K